[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported insider transactions dated 10/03/2025. Under a Rule 10b5-1 trading plan adopted on 12/12/2024, he exercised a stock option to acquire 10,000 shares at an exercise price of $9.15 per share and immediately sold 10,000 shares at a weighted-average price of $25.065 per share. The filings show the reporting person beneficially owned 21,831 shares before the sale and 11,831 shares after the sale; he also holds an option representing 10,000 underlying shares exercisable as of 10/03/2025 that expires on 03/14/2033, leaving 34,800 total shares and equivalents reported as beneficially owned following the transactions.

Positive

• Transactions executed under a Rule 10b5-1 plan, indicating pre-established trading parameters
• Realized proceeds from sale of 10,000 shares at a weighted-average $25.065 per share after exercising at $9.15

Negative

• Direct beneficial ownership fell by 10,000 shares, from 21,831 to 11,831
• Insider sale may reduce perceived insider-held stake in the near term

Insights

Corporate Insider Transactions Analyst

TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan, reducing direct holdings while realizing proceeds.

The reporting person exercised a stock option to buy $0.00 in cash beyond the stated exercise price of $9.15 per share for 10,000 shares and sold those 10,000 shares at a weighted-average price of $25.065. The transactions were made pursuant to a Rule 10b5-1 plan adopted on 12/12/2024, which is commonly used to provide an affirmative defense for scheduled trades.

Key dependencies and near-term monitorables include the continuing existence of the 10b5-1 plan and any future exercises or sales of derivative holdings; the option vesting schedule noted that vesting occurred monthly beginning 04/15/2023. Investors may note the reduction in direct beneficial ownership from 21,831 to 11,831 shares reported after the sale, while total reported economic exposure including options remains 34,800.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		M(1)		10,000	A	$9.15	21,831	D
Common Stock	10/03/2025		S(1)		10,000	D	$25.065(2)	11,831	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.15	10/03/2025		M(1)			10,000	(3)	03/14/2033	Common Stock	10,000	$0	34,800	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option vested or vests as to 1/48th of the total award on April 15, 2023, with an additional 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Stoke Therapeutics (STOK) Form 4 filed by Jonathan Allan report?

The Form 4 reports that Jonathan Allan exercised 10,000 option shares at $9.15 and sold 10,000 shares at a weighted-average price of $25.065 on 10/03/2025 under a Rule 10b5-1 plan.

How did the transactions change Jonathan Allan's beneficial ownership of STOK?

Reported direct beneficial ownership decreased from 21,831 shares to 11,831 shares after the sale; total reported exposure including options was 34,800 shares following the transactions.

Was the sale disclosed as part of a Rule 10b5-1 trading plan for STOK insider activity?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on 12/12/2024.

What option details were disclosed on the Form 4 for STOK?

The option exercised has an exercise price of $9.15, was exercisable on 10/03/2025, and expires on 03/14/2033; the option covered 10,000 underlying shares.

Did the Form 4 indicate the range of sale prices for the shares sold?

Yes. The filer reported a weighted-average sale price of $25.065 and stated the shares were sold in multiple transactions at prices ranging from $25.00 to $25.20.